Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies

Launched by HOPITAL FOCH · May 12, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the role of a type of immune cell called eosinophils in a group of lung diseases known as interstitial lung diseases (ILDs). These diseases can cause inflammation and scarring in the lungs, leading to difficulty breathing and other health issues. Researchers believe that eosinophils may play a part in worsening these conditions, and they want to study how these cells work in the lungs of patients with ILD. By understanding this better, they hope to find new treatment options for patients suffering from these challenging diseases.

To participate in the trial, patients need to be adults aged between 65 and 75 years with a specific history of ILD. They will be grouped based on their eosinophil levels—those with higher levels will be compared to those with lower levels. Participants can expect to provide biological samples and may be involved in laboratory studies to better understand the role of eosinophils in their condition. It’s important to know that certain patients, such as those with other specific lung diseases or serious health issues, will not be eligible for this trial. This research aims to pave the way for new therapies that could improve the lives of people with ILD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PID-PNE interest group (n= 30 patients): Adult subjects followed for chronic interstitial lung disease with a follow-up duration \> 1 year with at least one biological sample showing a circulating PNE level \> 300/mm3 during their follow-up, without any prescription of systemic corticosteroid therapy and antifibrotic agents (PIRFENIDONE and NINTENADIB) responsible for modulation of the eosinophil count.
• • 15 patients followed for Idiopathic Pulmonary Fibrosis (IPF) and 15 patients with another etiology of ILD will be selected.
• • PNE ILD control group (n= 30 patients): Adult subjects with ILD with a PNE level \< 150/mm3 during their follow-up, without any prescription of systemic corticosteroid therapy and antifibrotic agents (PIRFENIDONE and NINTENADIB). - Have signed a consent form.
• • Be affiliated with a health insurance plan.
• Exclusion Criteria:
• • Patients under 18 years of age
• • Patients over 75 years of age
• • Pregnant patients
• • Subjects with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
• • Subjects with hypereosinophilic syndrome (NEP \> 1500/mm3)
• • Subjects with chronic idiopathic eosinophilic pneumonia (Carrington disease)
• • Subjects with drug-induced interstitial lung disease
• • Subjects with respiratory failure (acute and chronic: SaO2 \> 92% throughout the procedure)
• • Subjects with unstable heart disease
• • Subjects with severe comorbidities
• • Subjects receiving oxygen therapy
• • Subjects deprived of liberty or under guardianship -Patients subject to a guardianship and judicial safeguard measure
• • PID-PNE or non-PID PNE patients receiving systemic corticosteroid therapy or antifibrotic treatment (PIRFENIDONE and NINTENADIB)